FDA
-
-
-
-
-
-
-
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
-
-
-
-
-
-
-
Summit Therapeutics plc (SMMT) PT Lowered to $30 at H.C. Wainwright
-
-
-
-
-
-
-
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Pos
-
-
-
-
-
-
-
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Summit Therapeutics Raises $500 Million in Private Placement
-
-
-
-
-
-
-
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
-
-
-
-
-
-
-
Piper Sandler Starts Summit Therapeutics plc (SMMT) at Neutral
-
322,964 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

